1. Home
  2. LPTX vs ALTS Comparison

LPTX vs ALTS Comparison

Compare LPTX & ALTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LPTX
  • ALTS
  • Stock Information
  • Founded
  • LPTX 2011
  • ALTS 1976
  • Country
  • LPTX United States
  • ALTS United States
  • Employees
  • LPTX N/A
  • ALTS N/A
  • Industry
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • ALTS
  • Sector
  • LPTX Health Care
  • ALTS
  • Exchange
  • LPTX Nasdaq
  • ALTS NYSE
  • Market Cap
  • LPTX 119.6M
  • ALTS 103.4M
  • IPO Year
  • LPTX N/A
  • ALTS N/A
  • Fundamental
  • Price
  • LPTX $0.36
  • ALTS $6.06
  • Analyst Decision
  • LPTX Buy
  • ALTS
  • Analyst Count
  • LPTX 2
  • ALTS 0
  • Target Price
  • LPTX $8.00
  • ALTS N/A
  • AVG Volume (30 Days)
  • LPTX 381.5K
  • ALTS 146.7K
  • Earning Date
  • LPTX 05-20-2025
  • ALTS 05-16-2025
  • Dividend Yield
  • LPTX N/A
  • ALTS N/A
  • EPS Growth
  • LPTX N/A
  • ALTS N/A
  • EPS
  • LPTX N/A
  • ALTS N/A
  • Revenue
  • LPTX N/A
  • ALTS $12,532,000.00
  • Revenue This Year
  • LPTX N/A
  • ALTS N/A
  • Revenue Next Year
  • LPTX N/A
  • ALTS N/A
  • P/E Ratio
  • LPTX N/A
  • ALTS N/A
  • Revenue Growth
  • LPTX N/A
  • ALTS N/A
  • 52 Week Low
  • LPTX $0.22
  • ALTS $1.29
  • 52 Week High
  • LPTX $4.79
  • ALTS $7.75
  • Technical
  • Relative Strength Index (RSI)
  • LPTX 45.04
  • ALTS 59.84
  • Support Level
  • LPTX $0.32
  • ALTS $5.50
  • Resistance Level
  • LPTX $0.38
  • ALTS $6.28
  • Average True Range (ATR)
  • LPTX 0.03
  • ALTS 0.64
  • MACD
  • LPTX 0.00
  • ALTS 0.03
  • Stochastic Oscillator
  • LPTX 37.36
  • ALTS 47.32

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

About ALTS ALT5 SIGMA CORPORATION

ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.

Share on Social Networks: